Cover Image

Chronic pain: the burden of disease and treatment innovations

S. Monti, R. Caporali
  • S. Monti
    Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia, Italy | sara.saramonti@gmail.com
  • R. Caporali
    Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia, Italy

Abstract

Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic impact. Effi cacy and tolerability problems are encountered with all therapeutic strategies available to treat musculoskeletal pain. This often limits effective analgesia and patients’ long term compliance, with the result that chronic pain is persistently underestimated and undertreated. Tapentadol is a novel, centrally acting analgesic that has been recently commercialized for the treatment of chronic pain. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI. Several studies demonstrated promising results in the management of both nociceptive and neuropathic pain and good tolerability profi le, particularly concerning side effects, compared to traditional opioids. This novel analgesic represents a possible therapeutic option also in the rheumatologic fi eld, particularly in the treatment of osteoarthritis and low back pain.

Keywords

musculoskeletal diseases, chronic pain, opioids, tapentadol.

Full Text:

PDF
Submitted: 2015-07-28 18:07:05
Published: 2015-10-23 12:50:21
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1414

Views:
PDF
1127

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2015 S. Monti, R. Caporali

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185